

Martin C Michel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11328517/martin-c-michel-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213
papers

9,513
citations

52
h-index

87
g-index

232
ext. papers

10,571
ext. citations

5.2
avg, IF

6.38
L-index

#	Paper	IF	Citations
213	Does coupling to ADP ribosylation factor 6 explain differences between muscarinic and other receptors in interaction with β adrenoceptor-mediated smooth muscle relaxation?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022 , 395, 381	3.4	0
212	What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.. <i>Advances in Therapy</i> , 2022 , 1	4.1	0
211	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022 , 1	3.4	1
210	Established and emerging treatments for diabetes-associated lower urinary tract dysfunction.. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022 , 1	3.4	0
209	Function and morphology of the urinary bladder after denervation. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021 , 320, R833-R834	3.2	0
208	Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2777-2789	3.8	3
207	Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
206	Medicamenteuze behandeling van de overactieve blaas: het heden en de toekomst. <i>Tijdschrift Voor Urologie</i> , 2021 , 11, 111-115	0.2	
205	Nicht-onkologische Arzneimitteltherapie 2021 , 85-118		
204	Cardiac and Vascular β Adrenoceptors in Congestive Heart Failure: A Systematic Review. <i>Cells</i> , 2020 , 9,	7.9	4
203	β Adrenoceptor activity of β adrenoceptor ligands - An expected drug property with limited clinical relevance. <i>European Journal of Pharmacology</i> , 2020 , 889, 173632	5.3	4
202	Impact of guideline awareness in public pharmacies on counseling of patients with acute or chronic constipation in a survey of pharmacy personnel. <i>BMC Gastroenterology</i> , 2020 , 20, 191	3	2
201	Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study. <i>Frontiers in Pharmacology</i> , 2020 , 11, 816	5.6	4
200	Where will the next generation of medical treatments for overactive bladder syndrome come from?. <i>International Journal of Urology</i> , 2020 , 27, 289-294	2.3	8
199	Expression and Signaling of β Adrenoceptor Subtypes in the Diabetic Heart. <i>Cells</i> , 2020 , 9,	7.9	4
198	A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes. <i>Cells</i> , 2020 , 9,	7.9	3
197	Building Robustness into Translational Research. <i>Handbook of Experimental Pharmacology</i> , 2020 , 257, 163-175	3.2	2

196	Normalization of organ bath contraction data for tissue specimen size: does one approach fit all?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020 , 393, 243-251	3.4	7
195	Agonist-induced desensitisation of β adrenoceptors: Where, when, and how?. <i>British Journal of Pharmacology</i> , 2019 , 176, 2539-2558	8.6	13
194	β Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?. <i>British Journal of Pharmacology</i> , 2019 , 176, 2525-2538	8.6	14
193	Cardiac β adrenoceptors-A role in human pathophysiology?. <i>British Journal of Pharmacology</i> , 2019 , 176, 2482-2495	8.6	11
192	Desensitization of cAMP Accumulation via Human β -Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. <i>Frontiers in Pharmacology</i> , 2019 , 10, 596	5.6	6
191	Cognitive and mood side effects of lower urinary tract medication. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 915-923	4.1	14
190	Why Are New Drugs Expensive and How Can They Stay Affordable?. <i>Handbook of Experimental Pharmacology</i> , 2019 , 260, 453-466	3.2	2
189	Biased Agonism in Drug Discovery-Is It Too Soon to Choose a Path?. <i>Molecular Pharmacology</i> , 2018 , 93, 259-265	4.3	57
188	Lower Urinary Tract Symptoms: What's New in Medical Treatment?. <i>European Urology Focus</i> , 2018 , 4, 17-24	5.1	14
187	Commentary on the BJP's new statistical reporting guidelines. <i>British Journal of Pharmacology</i> , 2018 , 175, 3636-3637	8.6	6
186	A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences. <i>Neurourology and Urodynamics</i> , 2018 , 37, 2346-2360	2.3	17
185	Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018 , 391, 675-694	3.4	18
184	The β adrenoceptor agonist mirabegron increases human atrial force through β adrenoceptors: an indirect mechanism?. <i>British Journal of Pharmacology</i> , 2017 , 174, 2706-2715	8.6	32
183	Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms. <i>International Journal of Clinical Practice</i> , 2017 , 71, e12907	2.9	7
182	Impact of Formulation on the Pharmacokinetic Profile of Dutasteride. <i>Clinical Drug Investigation</i> , 2016 , 36, 769-770	3.2	
181	Preclinical research strategies for newly approved drugs as reflected in early publication patterns. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016 , 389, 187-99	3.4	4
180	Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016 , 389, 201-9	3.4	4
179	Safety and tolerability of β -adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptome and experimental studies. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 647-57	4.1	26

178	Use of Antibodies in the Research on Muscarinic Receptor Subtypes. <i>Neuromethods</i> , 2016 , 83-94	0.4	1
177	Pathophysiological Factors in the Relationship between Chronological Age and Calculated Lung Age as Detected in a Screening Setting in Community-Dwelling Subjects. <i>Frontiers in Medicine</i> , 2016 , 3, 2	4.9	3
176	β-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in β-Adrenoceptor Knockout Mice. <i>Frontiers in Pharmacology</i> , 2016 , 7, 118	5.6	3
175	Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data. <i>Frontiers in Pharmacology</i> , 2016 , 7, 461	5.6	42
174	β-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. <i>Pharmacology & Therapeutics</i> , 2016 , 159, 66-82	13.9	35
173	Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. <i>Pharmacology & Therapeutics</i> , 2016 , 164, 1-81	13.9	42
172	Editorial Comment. <i>Journal of Urology</i> , 2016 , 196, 1808	2.5	1
171	Cellular basis of detrusor smooth muscle contraction. <i>BJU International</i> , 2016 , 117, 177-8	5.6	1
170	Therapeutic targets for overactive bladder other than smooth muscle. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 687-705	6.4	13
169	Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms. <i>American Journal of Physiology - Cell Physiology</i> , 2015 , 308, C505-20	5.4	18
168	β-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015 , 388, 749-59	3.4	14
167	Regulation of GAPDH expression by treatment with the β-adrenoceptor agonist isoprenaline--is GAPDH a suitable loading control in immunoblot experiments?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015 , 388, 1119-20	3.4	10
166	Therapeutic modulation of urinary bladder function: multiple targets at multiple levels. <i>Annual Review of Pharmacology and Toxicology</i> , 2015 , 55, 269-87	17.9	18
165	Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014 , 387, 215-24	3.4	22
164	The β-adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles with damaged endothelium. <i>British Journal of Pharmacology</i> , 2014 , 171, 3858-67	8.6	13
163	The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. <i>Pharmacological Reviews</i> , 2014 , 66, 222-307	22.5	327
162	Cardiovascular and ocular safety of β-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1187-97	4.1	28
161	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014 , 387, 505-21	3.4	84

160	The odd sibling: features of β -adrenoceptor pharmacology. <i>Molecular Pharmacology</i> , 2014 , 86, 479-84	4.3	53
159	Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. <i>Neurourology and Urodynamics</i> , 2014 , 33, 17-30	2.3	176
158	The pharmacological rationale for combining muscarinic receptor antagonists and β -adrenoceptor agonists in the treatment of airway and bladder disease. <i>Current Opinion in Pharmacology</i> , 2014 , 16, 31-42 ⁵¹	5.1	33
157	Rat β -adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014 , 387, 1117-27	3.4	16
156	Bradykinin contracts rat urinary bladder largely independently of phospholipase C. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014 , 348, 25-31	4.7	10
155	Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. <i>Neurourology and Urodynamics</i> , 2014 , 33, 106-14	2.3	37
154	Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014 , 387, 207-14	3.4	5
153	Agonist-induced desensitization of human β -adrenoceptors expressed in human embryonic kidney cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013 , 386, 843-51	3.4	13
152	A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. <i>Pharmacological Reviews</i> , 2013 , 65, 809-48	22.5	189
151	Agonist high- and low-affinity states of dopamine D_1 receptors: methods of detection and clinical implications. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013 , 386, 135-54	3.4	30
150	The new radioligand [(3)H]-L 748,337 differentially labels human and rat β -adrenoceptors. <i>European Journal of Pharmacology</i> , 2013 , 720, 124-30	5.3	19
149	Bradykinin modulates spontaneous nerve growth factor production and stretch-induced ATP release in human urothelium. <i>Pharmacological Research</i> , 2013 , 70, 147-54	10.2	20
148	Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases. <i>Pharmacological Research</i> , 2013 , 74, 1-6	10.2	20
147	EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. <i>European Urology</i> , 2013 , 64, 118-40	10.2	808
146	Are polymorphisms of the (β)-adrenoceptor gene associated with an altered bladder function?. <i>Neurourology and Urodynamics</i> , 2013 , 32, 276-80	2.3	11
145	Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. <i>Journal of the American Geriatrics Society</i> , 2013 , 61, 185-93	5.6	81
144	Editorial comment from Dr Michel to expression and functional role of β -adrenoceptors in the human ureter. <i>International Journal of Urology</i> , 2013 , 20, 1015	2.3	
143	Expression profiling of G-protein-coupled receptors in human urothelium and related cell lines. <i>BJU International</i> , 2012 , 110, E293-300	5.6	25

142	Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. <i>BJU International</i> , 2012 , 110, E422-8	5.6	20
141	Specificity evaluation of antibodies against human β -adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012 , 385, 875-82	3.4	28
140	A multicenter, double-blind, randomized, placebo-controlled trial of the β -adrenoceptor agonist solabegron for overactive bladder. <i>European Urology</i> , 2012 , 62, 834-40	10.2	77
139	A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. <i>European Urology</i> , 2012 , 62, 877-90	10.2	173
138	The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptoms. <i>Journal of Urology</i> , 2012 , 187, 1721-6	2.5	4
137	A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. <i>Frontiers in Pharmacology</i> , 2012 , 3, 93	5.6	34
136	Functional investigation of β adrenoceptors in human isolated detrusor focusing on the novel selective β -adrenoceptor agonist KUC-7322. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012 , 385, 759-67	3.4	20
135	β Adrenergic Receptor Subtypes in the Urinary Tract. <i>Handbook of Experimental Pharmacology</i> , 2011 , 307-18	3.2	21
134	Understanding Dose Titration: Overactive Bladder Treatment With Fesoterodine as an Example. <i>European Urology Supplements</i> , 2011 , 10, 8-13	0.9	12
133	Human Urinary Bladder Strip Relaxation by the β Adrenoceptor Agonist Isoprenaline: Methodological Considerations and Effects of Gender and Age. <i>Frontiers in Pharmacology</i> , 2011 , 2, 11	5.6	17
132	A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 235-46	3.8	114
131	Are there functional β adrenoceptors in the human heart?. <i>British Journal of Pharmacology</i> , 2011 , 162, 817-22	8.6	30
130	β Adrenoceptor agonist effects in experimental models of bladder dysfunction. <i>Pharmacology & Therapeutics</i> , 2011 , 131, 40-9	13.9	22
129	Lack of evidence that nebivolol is a β adrenoceptor agonist. <i>European Journal of Pharmacology</i> , 2011 , 654, 86-91	5.3	22
128	Desirable properties of β -adrenoceptor agonists: implications for the selection of drug development candidates. <i>European Journal of Pharmacology</i> , 2011 , 657, 1-3	5.3	8
127	The muscarinic receptor antagonist propiverine exhibits β 1)-adrenoceptor antagonism in human prostate and porcine trigonum. <i>World Journal of Urology</i> , 2011 , 29, 149-55	4	10
126	Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011 , 384, 555-63	3.4	15
125	Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. <i>Neurourology and Urodynamics</i> , 2011 , 30, 1227-41	2.3	96

124	Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. <i>Neurourology and Urodynamics</i> , 2011 , 30, 1480-5	2.3	28
123	Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. <i>Pharmacological Research</i> , 2011 , 64, 420-5	10.2	18
122	Pharmacology of Sexual Function 2011 , 139-145		
121	Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 177-88	6.2	37
120	The Pharmacological Profile of the α 1A-Adrenoceptor Antagonist Silodosin. <i>European Urology Supplements</i> , 2010 , 9, 486-490	0.9	12
119	The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability?. <i>Journal of Pharmacological Sciences</i> , 2010 , 112, 151-7	3.7	31
118	Sphingosine-1-phosphate regulates RGS2 and RGS16 mRNA expression in vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 2009 , 606, 25-31	5.3	7
117	Basic mechanisms of urgency: preclinical and clinical evidence. <i>European Urology</i> , 2009 , 56, 298-307	10.2	53
116	The effect of bladder outlet obstruction on alpha1- and beta-adrenoceptor expression and function. <i>Neurourology and Urodynamics</i> , 2009 , 28, 349-55	2.3	37
115	Activation of sphingosine kinase by muscarinic receptors enhances NO-mediated and attenuates EDHF-mediated vasorelaxation. <i>Basic Research in Cardiology</i> , 2009 , 104, 50-9	11.8	26
114	Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009 , 379, 397-402	3.4	112
113	Nocturia: a non-specific but important symptom of urological disease. <i>International Journal of Urology</i> , 2009 , 16, 249-56	2.3	39
112	Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors?. <i>British Journal of Pharmacology</i> , 2009 , 156, 127-34	8.6	38
111	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. <i>Current Opinion in Urology</i> , 2009 , 19, 380-94	2.8	143
110	Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?. <i>Current Opinion in Urology</i> , 2009 , 19, 13-9	2.8	23
109	Pharmacotherapy of Urgency Incontinence 2009 , 191-201		
108	Pharmacotherapy of Urgency Incontinence 2009 , 191-201		
107	Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. <i>European Journal of Pharmacology</i> , 2008 , 585, 278-91	5.3	67

106	S1P receptor signalling and RGS proteins; expression and function in vascular smooth muscle cells and transfected CHO cells. <i>European Journal of Pharmacology</i> , 2008 , 600, 1-9	5.3	15
105	Cholinergic innervation and muscarinic receptors in the human prostate. <i>European Urology</i> , 2008 , 54, 326-34	10.2	48
104	Physiological and pathological regulation of the autonomic control of urinary bladder contractility 2008 , 117, 297-312		70
103	Drug-induced urinary incontinence. <i>Drugs and Aging</i> , 2008 , 25, 541-9	4.7	51
102	Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1787-96	4	90
101	Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. <i>Pharmacological Reviews</i> , 2008 , 60, 513-35	22.5	28
100	Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008 , 377, 449-62	3.4	123
99	Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008 , 378, 217-24	3.4	14
98	Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008 , 378, 345-69	3.4	14
97	Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. <i>Pflugers Archiv European Journal of Physiology</i> , 2008 , 456, 349-58	4.6	8
96	Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?. <i>Neurourology and Urodynamics</i> , 2008 , 27, 226-30	2.3	43
95	Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?. <i>BJU International</i> , 2007 , 99, 749-52	5.6	110
94	Tools to study beta3-adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007 , 374, 385-98	3.4	81
93	Validation of a rapid, non-radioactive method to quantify internalisation of G-protein coupled receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007 , 375, 329-36	3.4	9
92	Pitfalls in the normalization of real-time polymerase chain reaction data. <i>Basic Research in Cardiology</i> , 2007 , 102, 195-7	11.8	55
91	Does phospholipase C mediate muscarinic receptor-induced rat urinary bladder contraction?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 322, 998-1002	4.7	28
90	Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007 , 1768, 994-1005	3.8	127
89	Epac and the cardiovascular system. <i>Current Opinion in Pharmacology</i> , 2007 , 7, 193-200	5.1	52

88	Vascular effects of sphingolipids. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007 , 96, 44-8	3.1	29
87	Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006 , 373, 37-44	3.4	15
86	Effects of gender, age and hypertension on beta-adrenergic receptor function in rat urinary bladder. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006 , 373, 300-9	3.4	49
85	How valid are animal models to evaluate treatments for pulmonary hypertension?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006 , 373, 391-400	3.4	58
84	Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006 , 374, 99-105	3.4	41
83	Tolerability of amine uptake inhibitors in urologic diseases. <i>Current Drug Safety</i> , 2006 , 1, 73-85	1.4	6
82	Sphingosine kinase-dependent activation of endothelial nitric oxide synthase by angiotensin II. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 2043-8	9.4	39
81	Tamsulosin [modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 237-246		7
80	Sequence of echocardiographic changes during development of right ventricular failure in rat. <i>Journal of the American Society of Echocardiography</i> , 2006 , 19, 1272-9	5.8	76
79	Effects of alpha(1)-adrenoceptor antagonists on male sexual function. <i>Drugs</i> , 2006 , 66, 287-301	12.1	95
78	Rho kinase: a target for treating urinary bladder dysfunction?. <i>Trends in Pharmacological Sciences</i> , 2006 , 27, 492-7	13.2	83
77	Sphingosine-1-phosphate and sphingosylphosphorylcholine: two of a kind?. <i>British Journal of Pharmacology</i> , 2006 , 147, 347-8	8.6	11
76	Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. <i>British Journal of Pharmacology</i> , 2006 , 147 Suppl 2, S88-119	8.6	319
75	Multiple gene approaches to delineate the role of the renin-angiotensin-aldosterone system in nephropathy. <i>Journal of Hypertension</i> , 2005 , 23, 269-72	1.9	2
74	The Neuro-Urological Connection. <i>European Urology Supplements</i> , 2005 , 4, 18-28	0.9	20
73	A role for muscarinic receptors or rho-kinase in hypertension associated rat bladder dysfunction?. <i>Journal of Urology</i> , 2005 , 173, 2178-81	2.5	28
72	Novel muscarinic antagonists to treat incontinence and/or overactive bladder. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005 , 2, 1-6		13
71	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. <i>BJU International</i> , 2005 , 95 Suppl 4, 19-28	5.6	39

70	Role of muscarinic receptor antagonists in urgency and nocturia. <i>BJU International</i> , 2005 , 96 Suppl 1, 37-42	5.6	32
69	Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. <i>European Urology</i> , 2005 , 48, 110-5	10.2	36
68	Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005 , 372, 71-8	3.4	45
67	Duloxetine in the treatment of stress urinary incontinence. <i>Women's Health</i> , 2005 , 1, 345-58	3	13
66	Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 313, 260-7	4.7	61
65	Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 308, 54-8	4.7	43
64	Signal transduction underlying carbachol-induced contraction of human urinary bladder. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 309, 1148-53	4.7	142
63	Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca ²⁺ sources. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 308, 47-53	4.7	71
62	Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. <i>British Journal of Pharmacology</i> , 2004 , 143, 666-84	8.6	112
61	Extracts from <i>Rhois aromatica</i> and <i>Solidaginis virgaurea</i> inhibit rat and human bladder contraction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004 , 369, 281-6	3.4	20
60	Small and intermediate conductance Ca ²⁺ -activated K ⁺ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004 , 369, 602-15	3.4	98
59	Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder?. <i>Journal of Urology</i> , 2004 , 172, 601-4	2.5	24
58	Association of hypertension with symptoms of benign prostatic hyperplasia. <i>Journal of Urology</i> , 2004 , 172, 1390-3	2.5	87
57	Safety of telmisartan in patients with arterial hypertension : an open-label observational study. <i>Drug Safety</i> , 2004 , 27, 335-44	5.1	44
56	Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003 , 367, 524-31	3.4	52
55	Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine. <i>British Journal of Pharmacology</i> , 2003 , 138, 261-71	8.6	20
54	Sphingosylphosphorylcholine, a naturally occurring lipid mediator, inhibits human platelet function. <i>British Journal of Pharmacology</i> , 2003 , 138, 435-44	8.6	10
53	Prevalence and physician awareness of symptoms of urinary bladder dysfunction. <i>European Urology</i> , 2002 , 41, 234-9	10.2	63

52	Problem- vs. lecture-based pharmacology teaching in a German medical school. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2002 , 366, 64-8	3.4	13
51	Transient relaxation of rat mesenteric microvessels by ceramides. <i>British Journal of Pharmacology</i> , 2002 , 135, 417-26	8.6	14
50	M(3) muscarinic receptors mediate contraction of human urinary bladder. <i>British Journal of Pharmacology</i> , 2002 , 136, 641-3	8.6	123
49	p38 MAP kinase is a mediator of ischemic preconditioning in pigs. <i>Cardiovascular Research</i> , 2002 , 55, 690-700	7.0	57
48	A benefit-risk assessment of extended-release oxybutynin. <i>Drug Safety</i> , 2002 , 25, 867-76	5.1	20
47	Comparison of problem-and lecture-based pharmacology teaching. <i>Trends in Pharmacological Sciences</i> , 2002 , 23, 168-70	13.2	48
46	An Extract From the Bark of <i>Aspidosperma Quebracho Blanco</i> Binds to Human Penile β -Adrenoceptors. <i>Journal of Urology</i> , 2002 , 168, 160-163	2.5	11
45	An extract from the bark of <i>Aspidosperma quebracho blanco</i> binds to human penile alpha-adrenoceptors. <i>Journal of Urology</i> , 2002 , 168, 160-3	2.5	4
44	Modulation of noradrenaline-induced microvascular constriction by protein kinase inhibitors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001 , 363, 57-65	3.4	12
43	Mitogen-activated protein kinases in the heart. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001 , 363, 245-66	3.4	84
42	In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic alpha1A- vs. alpha1B- and alpha1D-adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001 , 363, 649-62	3.4	27
41	Nifedipine inhibits sphingosine-1-phosphate-induced renovascular contraction in vitro and in vivo. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001 , 364, 179-82	3.4	23
40	The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 237-43	3.8	46
39	Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo?. <i>Prostate</i> , 2001 , 46, 226-32	3.2	15
38	Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. <i>British Journal of Pharmacology</i> , 2001 , 132, 1925-33	8.6	28
37	Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. <i>British Journal of Pharmacology</i> , 2000 , 130, 1871-7	8.6	85
36	Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. <i>British Journal of Pharmacology</i> , 2000 , 130, 1878-83	8.6	62
35	Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000 , 279, H1111-9	5.2	55

34	alpha(1)-adrenoceptor subtypes differentially couple to growth promotion and inhibition in Chinese hamster ovary cells. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 272, 906-11	3.4	46
33	EFFECT OF DIABETES ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2000 , 163, 1725-1729	2.5	129
32	Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 2657-63	4.3	21
31	Myocardial dysfunction in donor hearts. A possible etiology. <i>Circulation</i> , 1999 , 99, 2565-70	16.7	46
30	Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. <i>Prostate</i> , 1999 , 38, 208-15	4.2	67
29	CHARACTERIZATION OF α ADRENOCEPTOR SUBTYPES IN THE CORPUS CAVERNOSUM OF PATIENTS UNDERGOING SEX CHANGE SURGERY. <i>Journal of Urology</i> , 1999 , 162, 1793-1799	2.5	28
28	Differential regulation of 46 and 54 kDa jun N-terminal kinases and p38 mitogen-activated protein kinase by human alpha(1A)-adrenoceptors expressed in Rat-1 cells. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 261, 372-6	3.4	10
27	CHARACTERIZATION OF α ADRENOCEPTOR SUBTYPES IN THE CORPUS CAVERNOSUM OF PATIENTS UNDERGOING SEX CHANGE SURGERY. <i>Journal of Urology</i> , 1999 , 1793	2.5	4
26	Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. <i>Urological Research</i> , 1998 , 26, 149-54		40
25	Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 1998 , 45, 49-55	3.8	40
24	Differential alpha1-adrenoceptor labeling by [3H]prazosin and [3H]tamsulosin. <i>European Journal of Pharmacology</i> , 1998 , 342, 85-92	5.3	13
23	Stimulation of alpha1A-adrenoceptors in Rat-1 cells inhibits extracellular signal-regulated kinase by activating p38 mitogen-activated protein kinase. <i>Molecular Pharmacology</i> , 1998 , 54, 755-60	4.3	30
22	Tocolytic therapy with fenoterol induces selective down-regulation of beta-adrenergic receptors in human myometrium. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 1235-42	5.6	33
21	Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. <i>British Journal of Pharmacology</i> , 1997 , 120, 1335-43	8.6	45
20	Is alpha1D-adrenoceptor protein detectable in rat tissues?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997 , 355, 438-46	3.4	68
19	Prejunctional neuropeptide Y receptors in human kidney and atrium. <i>Journal of Cardiovascular Pharmacology</i> , 1997 , 29, 656-61	3.1	27
18	Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1995 , 352, 469-76	3.4	28
17	[Pro34]peptide YY is a Y1-selective agonist at peptide YY/neuropeptide Y receptors. <i>European Journal of Pharmacology</i> , 1994 , 269, 127-32		11

16	Sensitization by dexamethasone of lymphocyte cyclic AMP formation: evidence for increased function of the adenylyl cyclase catalyst. <i>British Journal of Pharmacology</i> , 1994 , 113, 240-6	8.6	21
15	Is PP56 (D-myo-inositol-1,2,6-trisphosphate) an antagonist at neuropeptide Y receptors?. <i>Life Sciences</i> , 1993 , 52, 1835-44	6.8	16
14	Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1993 , 347, 347-52	3.4	48
13	Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. <i>Journal of Cardiovascular Pharmacology</i> , 1992 , 19, 222-32	3.1	70
12	Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non-peptide antagonist. <i>British Journal of Pharmacology</i> , 1992 , 105, 71-6	8.6	29
11	NPY and carbachol raise Ca ²⁺ in SK-N-MC cells by three different mechanisms. Evidence for inositol phosphate-independent Ca ²⁺ mobilization by NPY. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1992 , 345, 370-4	3.4	14
10	Does verapamil act as an immunomodulatory drug in vivo?. <i>Immunopharmacology</i> , 1991 , 22, 85-91		2
9	Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. <i>Trends in Pharmacological Sciences</i> , 1991 , 12, 389-94	13.2	196
8	Renal alpha-adrenergic receptor alterations: a cause of essential hypertension?. <i>FASEB Journal</i> , 1989 , 3, 139-44	0.9	39
7	Interaction between alpha 2-adrenergic and NPY receptor pathways in human erythroleukemia cells. <i>Clinical and Experimental Hypertension</i> , 1989 , 11 Suppl 1, 281-6		2
6	Decreased myometrial beta-adrenoceptors in women receiving beta 2-adrenergic tocolytic therapy: correlation with lymphocyte beta-adrenoceptors. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 1-8	6.1	52
5	A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 46, 429-39	6.1	110
4	Elevation of plasma neuropeptide Y levels in congestive heart failure. <i>American Journal of Medicine</i> , 1989 , 86, 43-8	2.4	110
3	Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta 1- and beta 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. <i>Journal of the American College of Cardiology</i> , 1989 , 14, 323-31	15.1	126
2	Molecular mechanism of beta-adrenergic receptor blockers with intrinsic sympathomimetic activity. <i>FASEB Journal</i> , 1988 , 2, 2891-4	0.9	27
1	Arterial hypotension in chronic hemodialyzed patients. <i>Kidney International</i> , 1987 , 32, 728-35	9.9	50